cilnidipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium channel blockers, nifedipine derivatives	642	132203-70-4

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

FRC-8653
cilnidipine
cinaldipine
cinalong

has excitatory & inhibitory action on the Ca+ channels in the rabbit basilar artery; structure given in first source; RN given is for (+-) isomer

Molecular weight: 492.53
Formula: C27H28N2O7
CLOGP: 5.54
LIPINSKI: 1
HAC: 9
HDO: 1
TPSA: 117
ALOGS: -5.94
ROTB: 12

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal impairment	62.70	30.83	30	1013	88325	63399654
Hepatic function abnormal	47.10	30.83	19	1024	37123	63450856
Platelet count decreased	31.46	30.83	21	1022	116101	63371878

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral infarction	54.73	28.21	27	1739	27428	34927737
Renal impairment	50.15	28.21	40	1726	94473	34860692
Hyperkinetic heart syndrome	48.99	28.21	8	1758	120	34955045
Interstitial lung disease	48.89	28.21	34	1732	65248	34889917
Hepatic function abnormal	47.69	28.21	29	1737	44334	34910831
Stress cardiomyopathy	35.79	28.21	10	1756	2049	34953116
Cardiac vein perforation	35.52	28.21	5	1761	25	34955140
Echocardiogram abnormal	32.10	28.21	8	1758	1055	34954110

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Renal impairment	94.56	26.75	65	3065	157718	79583540
Hepatic function abnormal	90.42	26.75	48	3082	73059	79668199
Cerebral infarction	70.98	26.75	35	3095	45641	79695617
Interstitial lung disease	54.96	26.75	41	3089	112559	79628699
Hyperkinetic heart syndrome	50.40	26.75	8	3122	130	79741128
Hyperkalaemia	41.51	26.75	35	3095	114363	79626895
Hyperuricaemia	37.66	26.75	15	3115	11784	79729474
Cardiac vein perforation	36.77	26.75	5	3125	25	79741233
Platelet count decreased	35.70	26.75	41	3089	194623	79546635
Cerebral haemorrhage	35.01	26.75	24	3106	57649	79683609
Embolic stroke	32.31	26.75	12	3118	7814	79733444
Cardiac failure	30.74	26.75	34	3096	154808	79586450
Echocardiogram abnormal	28.23	26.75	8	3122	2220	79739038
Stress cardiomyopathy	28.18	26.75	12	3118	11154	79730104
Nephrogenic anaemia	27.83	26.75	9	3121	3893	79737365

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C08CA14	CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
CHEBI has role	CHEBI:35554	cardiovascular agent
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:38215	calcium channel blockers

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.67	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Voltage-gated L-type calcium channel	Ion channel	Q01668 Q13936	CAC1D_HUMAN CAC1C_HUMAN	BLOCKER				SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Voltage-dependent T-type calcium channel subunit alpha-1H	Ion channel	O95180	CAC1H_HUMAN		IC50	4.62		CHEMBL
Voltage-dependent N-type calcium channel subunit alpha-1B	Ion channel	Q00975	CAC1B_HUMAN		IC50	4.58		CHEMBL
Voltage-dependent N-type calcium channel subunit alpha-1B	Ion channel		CAC1B_RAT	BLOCKER	IC50	6.70		IUPHAR

External reference:

ID	Source
D01173	KEGG_DRUG
C0378675	UMLSCUI
CHEBI:31399	CHEBI
CHEMBL452076	ChEMBL_ID
DB09232	DRUGBANK_ID
C065927	MESH_SUPPLEMENTAL_RECORD_UI
7767	IUPHAR_LIGAND_ID
6880	INN_ID
97T5AZ1JIP	UNII
5282138	PUBCHEM_CID
010899	NDDF
1177123004	SNOMEDCT_US
1179035008	SNOMEDCT_US

Pharmaceutical products:

None